For the treatment of psoriasis, the following three IL-17-related monoclonal antibodies have been registered: secukinumab, ixekizumab, which directly blocks IL-17A, and brodalumab, which blocks IL-17A receptors [182]. This evidence concerns the gene IL17RA and psoriasis.